Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
19 hedge funds and large institutions have $48.8M invested in Iterum Therapeutics in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 12 reducing their positions, and 3 closing their positions.
55% more capital invested
Capital invested by funds: $31.6M → $48.8M (+$17.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.12% less ownership
Funds ownership: 2.97% → 2.85% (-0.12%)
14% less funds holding
Funds holding: 22 → 19 (-3)
92% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 12
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$917 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$414K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$99.6K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$88.7K |
| 4 |
NA
Neuburgh Advisers
Los Angeles,
California
|
-$72.8K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$60.4K |
ITRM Hedge Fund Activity: Q1 2019 in Review
19 of the 4,544 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q1 2019, worth a combined $48.8M — up 55% from $31.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ITRM and 0 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $917. The largest seller was Cormorant Asset Management, cutting an estimated $414K.
- 19 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2019, down from 22 in Q4 2018.
- Funds reported $48.8M of Iterum Therapeutics stock for Q1 2019, up 55% quarter-over-quarter.
- 0 funds opened new Iterum Therapeutics positions in Q1 2019 and 3 closed out, a net change of -3 holders.
- The largest Iterum Therapeutics buyer in Q1 2019 was Tower Research Capital (TRC), an estimated $917 added.
- The largest Iterum Therapeutics seller in Q1 2019 was Cormorant Asset Management, an estimated $414K sold.
Based on aggregated 13F filings for Q1 2019.